BIG 1-98 (IBCSG 18-98)

Intro text: 

A phase III study to evaluate letrozole as adjuvant endocrine therapy for postmenopausal women with receptor (ER and/or PgR) positive tumours identifier : NCT00004205

The BIG 1-98 study aimed to compare the effectiveness of letrozole with that of tamoxifen in treating postmenopausal women who have breast cancer that has been surgically removed.

Oestrogen can stimulate the growth of breast cancer cells. For postmenopausal women with hormone receptor-positive (HR+) breast cancer, giving tamoxifen as hormonal therapy after surgery (adjuvant) significantly prolongs disease-free and overall survival. Tamoxifen fights breast cancer by blocking the uptake of oestrogen by the tumour cells. Five years of treatment with tamoxifen reduces the risk of breast cancer recurrence by 47% and the risk of death by 26% among these patients. Despite these benefits, about half the women so treated still relapse. Also, tamoxifen treatment is associated with rare but serious side effects, including endometrial cancer and thromboembolism.

The aromatase inhibitor letrozole fights breast cancer by reducing the production of oestrogen. Previous studies have shown that letrozole is an effective treatment for metastatic breast cancer and is also more effective than tamoxifen when given before surgery (neoadjuvant therapy).

The objectives of BIG 1-98 were 1) to compare the efficacy of letrozole with that of tamoxifen administered as monotherapy during the first 5 years following breast cancer surgery (adjuvant therapy); and 2) to compare these treatment regimens given sequentially, with the final aim to determine the most effective approach to minimise the side effects and the risk of cancer recurrence.  

These different treatment regimens were compared in terms of overall survival, disease-free and systemic-free survival, safety, and tolerability.

Results of the study indicated that adjuvant treatment with letrozole, as compared with tamoxifen, significantly reduced the risk of recurrent disease, especially at distant sites; it proved to be an effective option for standard adjuvant therapy, with a relatively favorable safety profile in postmenopausal women with hormone receptor-positive breast cancer.

Together with the BIG 1-97/MA.17 and BIG 2-97/IES studies, BIG 1-98 contributed to the body of evidence that aromatase inhibitors could be used as a safe alternative to tamoxifen, a drug used to treat oestrogen receptor-positive (ER+) breast cancer that is associated with dangerous side effects for some women.

Postmenopausal women with operable, hormone receptor-positive breast cancer.

A total of 8,010 women with data that could be assessed were enrolled in this study.

This study was coordinated and sponsored by the International Breast Cancer Study Group (IBCSG) and was conducted under the Breast International Group (BIG) umbrella. Eight BIG groups, several independent groups, and a total of 245 hospitals participated.

Patients were assigned to four different treatment groups, each receiving a different endocrine therapy after surgery: either 5 years of monotherapy with tamoxifen (group 1) or with letrozole (group 2), or sequences of 2 years of one followed by 3 years of the other (groups 3 and 4). The enhanced design of the trial enabled two complementary analyses of efficacy and safety.

Collection of tumour specimens further enabled treatment comparisons based on tumour biology.

Between March 1998 and May 2003, 8,028 patients were recruited in this trial. 18 withdrew consent and did not start treatment, leaving 8,010 patients.

The main results were published in 2005 in the New England Journal of Medicine.

Many reports and analyses related to the BIG 1-98 study have been published. Listed below are the publications of the main results and study follow-up.

View all publications related to BIG 1-98 here

Novartis provided drugs and funding for this study, which was run according to BIG’s Principles or Research Conduct.